Sign In
Buy RSLS
$3.92
+0 (+0%)
At Close: Nov 13, 2025
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
08:31am, Wednesday, 21'st May 2025
IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial result
Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:32am, Monday, 12'th May 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 700 points on Monday.
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
08:31am, Wednesday, 07'th May 2025
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board
Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
08:31am, Monday, 28'th Apr 2025
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowab
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatibl
ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)
05:54pm, Thursday, 10'th Apr 2025
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Earnings Highlights and Strategic Business Update Conference April 10, 2025 4:30 PM ET Company Participants Michael Miller - IR, Rx Communications Paul Hickey
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
04:05pm, Wednesday, 09'th Apr 2025
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
04:05pm, Monday, 07'th Apr 2025
Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of
Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
08:31am, Tuesday, 25'th Feb 2025
Liaison Medical is Among the Largest Surgical Device Distributors in Canada Liaison Medical is Among the Largest Surgical Device Distributors in Canada
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
11:17pm, Saturday, 15'th Feb 2025
IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions c
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
08:31am, Monday, 03'rd Feb 2025
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia
IRVINE, Calif. and CAMBRIDGE, Mass.
